TIDMFUM
RNS Number : 4938V
Futura Medical PLC
14 April 2021
14 April 2021
Remuneration of Non-Executive Directors and Total Voting
Rights
Futura Medical plc (AIM: FUM) (the "Company), a pharmaceutical
company developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology and currently
focused on sexual health and pain, announces the issue of 176,318
new ordinary shares of 0.2 pence each ("Ordinary Shares") in
respect of the 2020 remuneration of its Non-Executive
Directors.
In accordance with the terms of their service agreements, the
Non-Executive Directors annually receive approximately 30 per cent
of their remuneration in the form of Ordinary Shares. For 2020,
these were issued at 12.24 pence per share, being the average
closing mid-market price of the last 10 trading days of 2019 (as
announced via RNS on 22 January 2020).
The 176,318 new Ordinary Shares shall rank pari passu with the
existing issued Ordinary Shares of the Company and have been issued
as follows:
Director Number of Ordinary Shares Total number of ordinary shares Percentage of the Company's
issued for 2020 remuneration held resulting issued share capital
John Clarke 129,754 642,542 0.26%
Jonathan Freeman 46,564 222,282 0.09%
Application has been made to the London Stock Exchange and it is
anticipated that trading of the new Ordinary Shares will commence
on AIM at 8:00am on 20 April 2021.
Immediately following the above issue, the Company will have
248,500,971 ordinary shares in issue, each carrying one voting
right. Since the Company currently holds no shares in treasury, the
total number of voting rights in the Company is therefore
248,500,971 and this figure may be used by Shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change in their
interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
The shares element of the Non-Executive Directors' remuneration
for 2021 will be awarded at 14.97 pence per Ordinary Share, being
the average closing mid-market price of the last 10 trading days of
2020. The Non-Executive Directors will receive these shares in
January 2022.
Further details are contained within the notifications below,
made in accordance with Article 19 of the EU Market Abuse
Regulation 596/2014. Full details of the Non-Executive Directors'
remuneration will be included in the Company's Annual Report &
Accounts.
S
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.Futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Richard Lindley/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 922 0900
Notes to editors
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction (ED) through a
unique evaporative mode of action. Futura has conducted a Phase 3
study using MED3000 in ED, referred to as "FM57". This was a 1,000
patient, dose-ranging, multi-centre, randomised, double blind,
placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment
baseline, consistently meeting all co-primary endpoints of IIEF,
SEP2 and SEP3 (internationally accepted clinical trial endpoints in
ED) with over 60% of patients experiencing a clinically meaningful
improvement in their ED. MED3000 also begins to work immediately in
some patients, with 60% of patients seeing onset of their erection
within 10 minutes of application.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name John Clarke
------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Director/ PDMR
------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Futura Medical plc
------------------------------ -----------------------------------
b) LEI 21380053QLT46UNV2303
------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the
financial instrument, Ordinary shares of 0.2p each
type of instrument
GB0033278473
Identification code
------------------------------ -----------------------------------
b) Nature of the transaction Issue of shares
------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
12.24 pence 129,754
----------
------------------------------ -----------------------------------
d) Aggregated information
- Aggregated volume
Not applicable
- Price
------------------------------ -----------------------------------
e) Date of the transaction 14 April 2021
------------------------------ -----------------------------------
f) Place of the transaction Outside of trading venue
------------------------------ -----------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Jonathan Freeman
------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Director/ PDMR
------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Futura Medical plc
------------------------------ -----------------------------------
b) LEI 21380053QLT46UNV2303
------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the
financial instrument, Ordinary shares of 0.2p each
type of instrument
GB0033278473
Identification code
------------------------------ -----------------------------------
b) Nature of the transaction Issue of shares
------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
12.24 pence 46,564
----------
------------------------------ -----------------------------------
d) Aggregated information
- Aggregated volume
Not applicable
- Price
------------------------------ -----------------------------------
e) Date of the transaction 14 April 2021
------------------------------ -----------------------------------
f) Place of the transaction Outside of trading venue
------------------------------ -----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBSGDSRXBDGBS
(END) Dow Jones Newswires
April 14, 2021 10:40 ET (14:40 GMT)
Futura Medical (LSE:FUM)
Historical Stock Chart
From Apr 2024 to May 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From May 2023 to May 2024